Next Article
Why Sun Pharma's stock fell despite solid annual growth
Sun Pharma's stock dropped 2.29% to ₹1,618.70 on Tuesday, August 26, 2025—even though the company just posted solid annual growth.
For the year ending March 2025, revenue climbed to ₹52,578 crore from last year's ₹48,497 crore.
Annual results show net profit jumped to ₹10,980 crore
Despite net profit jumping to ₹10,980 crore and earnings per share rising to ₹45.60 for FY25—with a super-low debt-to-equity ratio of 0.03 and steady returns—investors seemed wary because of recent quarterly results.
Recent quarterly results may have spooked investors
From April to June 2025, revenue grew compared to the same time last year but net profit actually dropped from ₹2,871 crore to ₹2,303 crore.
This dip may have made investors pause despite Sun Pharma's overall healthy numbers.